Skip to content
The Nexus
DossierENTITY

Jan Janisch-Hanzlik

Coverage of Jan Janisch-Hanzlik in the Nexus archive.

Earliest in view: May 17 · 11:00 UTCMost recent: May 17 · 11:00 UTC
Co-mentioned in this coverage
University of Nebraska Medical Centerorganization1CAR T cell therapytopic1Multiple Sclerosistopic1Lupustopic1Graves' diseasetopic1Omahaplace1
Recent coverage
  • HEALTHMay 17 · 11:00 UTCARS TECHNICA
    A revolutionary cancer treatment could transform autoimmune disease

    Jan Janisch-Hanzlik, a 49-year-old multiple sclerosis patient, participated in a CAR T cell therapy trial at the University of Nebraska Medical Center, which aims to transform autoimmune disease treatment by reprogramming immune cells. The therapy, originally designed for cancer, is being tested in hundreds of clinical trials for conditions like lupus and Graves' disease. If successful, it could reset the body's defenses to a pre-disease state.

Jan Janisch-Hanzlik · Dossier · The Nexus